Editas Medicine Q4 Earnings Preview

On Tuesday, Editas Medicine, Inc. - Common Stock EDIT will release its latest earnings report. Decipher the announcement with Benzinga's help.

Earnings and Revenue

Wall Street analysts see Editas Medicine reporting a quarterly loss of 75 cents per share on sales of $4.13 million.

In the same quarter last year, Editas Medicine posted an EPS loss of $1.10 on sales of $898,000. If the company were to match the consensus estimate when it reports Tuesday, sales would be up 359.91 percent from the same quarter last year.

Here's how the Editas Medicine reported EPS has stacked up against analyst estimates in the past:

Stock Performance

Over the last 52-week period, shares are up 60.64 percent. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. Analysts' have adjusted their estimates higher for EPS and revenues over the past 90 days. The average rating by analysts on Editas Medicine stock is a Neutral. The validity of this rating has risen over the past 90 days.

Conference Call

Editas Medicine's conference call is scheduled to begin at 5:00 p.m. ET and can be accessed here.